The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.
about
Hepatitis B virus therapy: What's the future holding for us?Recent advances of vaccine adjuvants for infectious diseasesIdentification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen.Hepatitis B vaccine adverse events in China: risk control and regulation.Adjuvants for vaccines to drugs of abuse and addiction.Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune PotentiatorsA CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates.Hepatitis B vaccination: needs a revision.Recent progress concerning CpG DNA and its use as a vaccine adjuvant.Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.Prevention of hepatitis B virus infection: from the past to the future.Overview of Vaccine Adjuvants: Introduction, History, and Current Status.An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.Protective immunity differs between routes of administration of attenuated malaria parasites independent of parasite liver load.
P2860
Q26774198-C1432DDF-EB58-474D-9755-3FD984D62DE5Q28083679-AAAEA2A1-4892-4B79-A914-17891F489F41Q30388683-4935EF77-6CCA-462D-B010-C28918BC5FB7Q33723418-AFCF8B7F-08A0-474A-BD34-F95ED24E4135Q35493923-E969B9F3-E9B3-4581-BA18-F250C8CD83ABQ35826747-E7915670-ECDB-47C2-AD56-CA7062E7DE74Q35853440-236EB071-9DCB-4F07-8E50-5C5D27AA4B32Q36933639-A05EA730-FCDD-444B-B9EC-3572ECC15270Q37699261-BD9A2F9B-478E-413D-90A3-6EAE0FCAE691Q38168903-ED154B86-F325-4B40-913A-00368877AF1AQ38306933-9AC09CD9-7CA5-41B5-9CDB-C45998E80A63Q38354222-BB11538E-7A4C-46B9-9EF9-EFB712F3AB0FQ38813523-70D83777-FDB4-4755-A4C2-2FC36D9B4F51Q39174792-78A7432E-D5F1-4934-B51B-0B4880D8E7FEQ40067174-A34A03CB-3D0F-4F8F-A3FD-133A2CD60A08
P2860
The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.
@en
type
label
The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.
@en
prefLabel
The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.
@en
P2093
P2860
P356
P1476
The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.
@en
P2093
Francisco Diaz-Mitoma
Nelson F Eng
Nitin Bhardwaj
Rebecca Mulligan
P2860
P304
P356
10.4161/HV.24715
P577
2013-05-31T00:00:00Z